Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025
Integrated BioPharma (OTCQX:INBP) reported its financial results for Q4 and fiscal year 2025. The company achieved Q4 revenue of $14.2 million, up 11.8% year-over-year, and full-year revenue of $54.3 million, an 8.0% increase from FY2024.
For FY2025, INBP reported net income of $808,000 ($0.03 per share), compared to $112,000 in FY2024. However, Q4 2025 saw a net loss of $0.2 million (-$0.01 per share), versus net income of $0.3 million in Q4 2024. The company's Contract Manufacturing Segment showed strong customer concentration, with two largest customers representing 84% of total revenue in FY2025, down from 90% in FY2024.
Integrated BioPharma (OTCQX:INBP) ha riportato i risultati finanziari per il Q4 e per l'anno fiscale 2025. L'azienda ha raggiunto ricavi del Q4 di 14,2 milioni di dollari, in aumento dell'11,8% rispetto all'anno precedente, e ricavi annui per l'intero anno di 54,3 milioni di dollari, in crescita dell'8,0% rispetto al FY2024.
Per l'FY2025, INBP ha riportato utile netto di 808.000 dollari (0,03 dollari per azione), rispetto a 112.000 dollari nell'FY2024. Tuttavia, nel Q4 2025 si è registrato una perdita netta di 0,2 milioni di dollari (-0,01 dollari per azione), rispetto a un utile netto di 0,3 milioni nel Q4 2024. Il segmento Contract Manufacturing ha mostrato una forte concentrazione della clientela, con i due maggiori clienti a rappresentare l'84% del totale dei ricavi nell'FY2025, rispetto al 90% nell'FY2024.
Integrated BioPharma (OTCQX:INBP) informó sus resultados financieros para el cuarto trimestre y el año fiscal 2025. La empresa logró ingresos del Q4 de 14,2 millones de dólares, un aumento del 11,8% interanual, y ingresos anuales del año completo de 54,3 millones de dólares, un incremento del 8,0% respecto al FY2024.
Para el FY2025, INBP reportó utilidad neta de 808.000 dólares (0,03 por acción), frente a 112.000 dólares en el FY2024. Sin embargo, el Q4 2025 mostró una pérdida neta de 0,2 millones de dólares (-0,01 por acción), frente a una utilidad neta de 0,3 millones en el Q4 2024. El segmento de Contract Manufacturing mostró una fuerte concentración de clientes, con los dos mayores clientes representando el 84% del total de ingresos en el FY2025, frente al 90% en el FY2024.
Integrated BioPharma (OTCQX:INBP)는 2025년 회계연도 4분기 및 연간 실적을 발표했습니다. 회사는 4분기 매출 1420만 달러, 전년 동기 대비 11.8% 증가, 그리고 연간 매출 5430만 달러, FY2024 대비 8.0% 증가를 달성했습니다.
FY2025 기준 INBP는 순이익 80.8만 달러(주당 0.03달러)를 보고했으며, FY2024의 11.2만 달러와 비교됩니다. 다만, 2025년 4분기는 순손실 20만 달러(-주당 -0.01달러)를 기록했으며, 2024년 4분기 순이익은 30만 달러였습니다. 회사의 Contract Manufacturing 부문은 두 개의 주요 고객이 총 매출의 84%를 차지하는 고객 집중이 강한 모습을 보였으며, FY2025에서 90%에서 하락했습니다.
Integrated BioPharma (OTCQX:INBP) a publié ses résultats financiers pour le 4e trimestre et l'exercice 2025. L'entreprise a enregistré un chiffre d'affaires du T4 de 14,2 millions de dollars, en hausse de 11,8% d'une année sur l'autre, et un chiffre d'affaires annuel de l'exercice complet de 54,3 millions de dollars, en augmentation de 8,0% par rapport au FY2024.
Pour FY2025, INBP a déclaré un bénéfice net de 808 000 dollars (0,03 dollar par action), contre 112 000 dollars en FY2024. Cependant, le T4 2025 a connu une perte nette de 0,2 million de dollars (-0,01 dollar par action), contre un bénéfice net de 0,3 million au T4 2024. Le segment Contract Manufacturing a montré une forte concentration de clients, avec les deux plus gros clients représentant 84% du total des revenus en FY2025, contre 90% en FY2024.
Integrated BioPharma (OTCQX:INBP) hat seine Finanzergebnisse für das Q4 und das Geschäftsjahr 2025 bekannt gegeben. Das Unternehmen erzielte Q4-Umsatz von 14,2 Mio. $, eine Steigerung von 11,8% gegenüber dem Vorjahr, sowie das Jahresumsatz von 54,3 Mio. $, eine Steigerung von 8,0% gegenüber FY2024.
Für FY2025 meldete INBP Nettoeinkommen von 808.000 $ (0,03 $ pro Aktie), verglichen mit 112.000 $ im FY2024. Allerdings wies Q4 2025 einen Nettoverlust von 0,2 Mio. $ (-0,01 $ pro Aktie) aus, gegenüber Nettoergebnis von 0,3 Mio. $ im Q4 2024. Das Contract Manufacturing-Segment des Unternehmens zeigte eine starke Kundenkonzentration, wobei zwei Largest Customers 84% des Gesamtertrags in FY2025 ausmachten, verglichen mit 90% in FY2024.
Integrated BioPharma (OTCQX:INBP) أصدرت نتائجها المالية للربع الرابع والسنة المالية 2025. حققت الشركة إيرادات الربع الرابع قدرها 14.2 مليون دولار، بارتفاع قدره 11.8% على أساس سنوي، وإيرادات السنة الكلية قدرها 54.3 مليون دولار، بزيادة 8.0% عن FY2024.
بالنسبة للسنة المالية 2025، أعلنت INBP صافي دخل قدره 808,000 دولار (0.03 دولار للسهم)، مقارنةً بـ 112,000 دولار في FY2024. ومع ذلك، شهد الربع الرابع من 2025 خسارة صافية قدرها 0.2 مليون دولار (-0.01 دولار للسهم)، مقابل صافي دخل قدره 0.3 مليون دولار في الربع الرابع 2024. أظهر قطاع Contract Manufacturing تركيزاً قوياً على العملاء، حيث مثل أكبر عميلين 84% من إجمالي الإيرادات في FY2025، انخفاضاً من 90% في FY2024.
Integrated BioPharma (OTCQX:INBP) 报告了2025财年第四季度和全年业绩。公司实现了 第四季度收入为1420万美元，同比增长11.8%，以及 全年收入为5430万美元，较2024财年增长8.0%。
就2025财年而言，INBP 报告的 净利润为80.8万美元（每股0.03美元），相比2024财年的11.2万美元。然而，2025年第四季度出现了 净亏损20万美元（每股亏损0.01美元），相比2024年第四季度的净利润为30万美元。公司的Contract Manufacturing部门显示出较强的客户集中度，前两大客户在2025财年占总收入的84%，低于2024财年的90%。
- Revenue increased 8.0% year-over-year to $54.3 million in FY2025
- Q4 2025 revenue grew 11.8% to $14.2 million
- FY2025 net income increased significantly to $808,000 from $112,000 in FY2024
- Customer base expansion reduced concentration risk from 90% to 84% for top two customers
- Operating income improved to $2.02 million in FY2025 from $251,000 in FY2024
- Q4 2025 resulted in a net loss of $0.2 million, compared to $0.3 million profit in Q4 2024
- High customer concentration with 84% of revenue from just two customers
- Significant increase in income tax expense to $1.25 million in FY2025 from $156,000 in FY2024
HILLSIDE, NJ / ACCESS Newswire / September 23, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2025.
Revenue for the quarter ended June 30, 2025 was
Revenues for the fiscal year ended June 30, 2025 were
For the quarter ended June 30, 2025, the Company had a net loss of approximately
For the fiscal year ended June 30, 2025, the Company had net income of approximately
"Our revenues increased by
A summary of our financial results for the three months and fiscal years ended June 30, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES | ||||||||||||||||
CONSOLIDATED STATEMENTS OF INCOME | ||||||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Fiscal Year Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Total revenue | $ | 14,175 | $ | 12,746 | $ | 54,353 | $ | 50,317 | ||||||||
Cost of sales | 12,706 | 11,462 | 48,791 | 46,433 | ||||||||||||
Gross profit | 1,469 | 1,284 | 5,562 | 3,884 | ||||||||||||
Selling and administrative expenses | 880 | 882 | 3,542 | 3,633 | ||||||||||||
Operating income | 589 | 402 | 2,020 | 251 | ||||||||||||
Other income, net | 6 | 12 | 42 | 17 | ||||||||||||
Income before income taxes | 595 | 414 | 2,062 | 268 | ||||||||||||
Income tax expense, net | 773 | 146 | 1,254 | 156 | ||||||||||||
Net (loss) income | $ | (178 | ) | $ | 268 | $ | 808 | $ | 112 | |||||||
Net (loss) income per common share: | ||||||||||||||||
Basic | $ | (0.01 | ) | $ | 0.01 | $ | 0.03 | $ | 0.00 | |||||||
Diluted | $ | (0.01 | ) | $ | 0.01 | $ | 0.03 | $ | 0.00 | |||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 30,622,045 | 30,099,610 | 30,295,655 | 30,066,003 | ||||||||||||
Diluted | 30,622,045 | 30,702,683 | 31,168,372 | 30,873,681 | ||||||||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What were Integrated BioPharma's (INBP) earnings per share for fiscal year 2025?
How much revenue did INBP generate in Q4 2025?
What was INBP's customer concentration in fiscal year 2025?
What was Integrated BioPharma's operating income for fiscal year 2025?
How did INBP perform in Q4 2025 compared to Q4 2024?
